文献速递骨质疏松与代谢性骨病

基线骨转换标志物水平可预测骨质疏松患者抗骨吸收治疗期间骨密度变化:哥本哈根骨转换标志物研究

Baseline bone turnover marker levels can predict change in bone mineral density during antiresorptive treatment in osteoporotic patients: the Copenhagen bone turnover marker study.
PubMed 文献 · Osteoporos Int · 2022-06-21

该注册队列研究纳入158例接受抗骨吸收治疗的骨质疏松患者,按治疗前CTX和/或PINP水平分组,分析其与腰椎、全髋和股骨颈骨密度变化的关系。结果发现治疗前CTX和PINP高于绝经前女性几何均值者,全髋和腰椎骨密度年增幅更大。结论认为治疗前骨转换标志物水平可预测抗骨吸收治疗的骨密度反应。

要点

  • 治疗前CTX高于几何均值者全髋骨密度年增幅大于低于几何均值者(p=0.008)。
  • 治疗前CTX数值与全髋(p=0.03)、股骨颈(p=0.04)、腰椎(p=0.0003)骨密度年增幅相关。
  • 治疗前PINP高于几何均值者全髋(p=0.02)和腰椎(p=0.006)骨密度年增幅更大。

核心结论

  • 测量治疗前骨转换标志物水平可预测骨质疏松患者对抗骨吸收治疗的反应。
  • 治疗前CTX和/或PINP水平高的患者比水平低的患者从抗骨吸收治疗中获益更多,骨密度增幅更大。

研究设计与样本

  • 基于注册的队列研究,纳入158例接受抗骨吸收治疗的骨质疏松患者。
  • 检测治疗前血浆I型胶原C端肽(CTX)和/或I型前胶原N端前肽(PINP)水平,按绝经前女性几何均值分为高于和低于两组。
  • 分析治疗前骨转换标志物水平与腰椎、全髋和股骨颈骨密度变化的关系。

主要发现

  • 治疗前CTX高于几何均值者全髋骨密度年增幅大于低于几何均值者(p=0.008)。
  • 治疗前CTX数值与全髋(p=0.03)、股骨颈(p=0.04)和腰椎(p=0.0003)骨密度年增幅相关。
  • 治疗前PINP高于几何均值者全髋(p=0.02)和腰椎(p=0.006)骨密度年增幅更大。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Anti-resorptive osteoporosis treatment might be more effective in patients with high bone turnover. In this registry study including clinical data, high pre-treatment bone turnover measured with biochemical markers was correlated with higher bone mineral density increases. Bone turnover markers may be useful tools to identify patients benefitting most from anti-resorptive treatment. INTRODUCTION: In randomized, controlled trials of bisphosphonates, high pre-treatment levels of bone turnover markers (BTM) were associated with a larger increase in bone mineral density (BMD). The purpose of this study was to examine this correlation in a real-world setting. METHODS: In this registry-based cohort study of osteoporosis patients (n = 158) receiving antiresorptive therapy, the association between pre-treatment levels of plasma C-telopeptide of type I Collagen (CTX) and/or N-terminal propeptide of type I procollagen (PINP) and change in bone mineral density (BMD) at lumbar spine, total hip, and femoral neck upon treatment was examined. Patients were grouped according to their pre-treatment BTM levels, defined as values above and below the geometric mean for premenopausal women. RESULTS: Pre-treatment CTX correlated with annual increase in total hip BMD, where patients with CTX above the geometric mean experienced a larger annual increase in BMD (p = 0.008) than patients with CTX below the geometric mean. The numerical pre-treatment level of CTX showed a similar correlation at all three skeletal sites (total hip (p = 0.03), femoral neck (p = 0.04), and lumbar spine (p = 0.0003)). A similar association was found for PINP where pre-treatment levels of PINP above the geometric mean correlated with a larger annual increase in BMD for total hip (p = 0.02) and lumbar spine (p = 0.006). CONCLUSION: Measurement of pre-treatment BTM levels predicts osteoporosis patients' response to antiresorptive treatment. Patients with high pre-treatment levels of CTX and/or PINP benefit more from antiresorptive treatment with larger increases in BMD than patients with lower pre-treatment levels.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Bønløkke SE, Rand MS, Haddock B, et al. Baseline bone turnover marker levels can predict change in bone mineral density during antiresorptive treatment in osteoporotic patients: the Copenhagen bone turnover marker study. Osteoporos Int. 2022. PMID: 35729342. doi:10.1007/s00198-022-06457-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。